Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Laura Agresta"'
Autor:
Laura Agresta, Maria Lehn, Kristin Lampe, Rachel Cantrell, Cassandra Hennies, Sara Szabo, Trisha Wise-Draper, Kasper Hoebe, Edith M Janssen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundDeveloping novel strategies to overcome the immunosuppressive tumor microenvironment is a critically important area of cancer therapy research. Here, we assess the therapeutic potential of CD244 (2B4/signaling lymphocyte activation molecule
Externí odkaz:
https://doaj.org/article/399509727da14162bd5e3fe439ed4134
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
In cancer, immune exhaustion contributes to the immunosuppressive tumor microenvironment. Exhausted immune cells demonstrate poor effector function and sustained expression of certain immunomodulatory receptors, which can be therapeutically targeted.
Externí odkaz:
https://doaj.org/article/0d0070f3e79f41cba04318bfd7a9bdfb
Autor:
Benjamin Mizukawa, Vanessa A Fabrizio, Neerav Shukla, Sharon M. Castellino, Daniel S. Wechsler, Marilyn Winchester, Nancy Bouvier, Ahmet Zehir, Brian Turpin, David S. Shulman, Himalee S. Sabnis, Jason Fangusaro, Julia Glade-Bender, Steven G. DuBois, Chanta Whitlow, Laura Agresta
Publikováno v:
J Clin Oncol
PURPOSE The US Food and Drug Administration–expanded access program (EAP) uses a single patient use (SPU) mechanism to provide patient access to investigational agents in situations where no satisfactory or comparable therapy is available. Genomic
Autor:
Edith M Janssen, Sara Szabo, Rachel Cantrell, Kasper Hoebe, Laura Conforti, Maria A. Lehn, Trisha Wise-Draper, Kristin Lampe, Laura Agresta, Cassandra M. Hennies
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundDeveloping novel strategies to overcome the immunosuppressive tumor microenvironment is a critically important area of cancer therapy research. Here, we assess the therapeutic potential of CD244 (2B4/signaling lymphocyte activation molecule
Autor:
Alexander A. Vinks, Robin E. Norris, Maureen M. O'Brien, Pankaj B. Desai, H. Leighton Grimes, Michael J. Absalon, Eric O'Brien, John P. Perentesis, Thomas J. Ryan, Karen Burns, Erin H. Breese, Benjamin Mizukawa, Laura Agresta
Publikováno v:
Journal of Clinical Oncology. 39:TPS7052-TPS7052
TPS7052 Background: Despite significant advances in therapy for acute myeloid leukemia (AML), 30-40% of young patients will relapse, after which prognosis is poor. In young patients, curative-intent salvage therapy involves intensive re-induction fol
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
In cancer, immune exhaustion contributes to the immunosuppressive tumor microenvironment. Exhausted immune cells demonstrate poor effector function and sustained expression of certain immunomodulatory receptors, which can be therapeutically targeted.
Autor:
Daniel S. Wechsler, Laura Agresta, Sharon M. Castellino, Marilyn Winchester, Benjamin Mizukawa, Himalee S. Sabnis, Chanta Whitlow, Brian Turpin, Stephen S. Roberts, Neerav Shukla, Maureen M. O'Brien, Julia Glade-Bender, Jason Fangusaro
Publikováno v:
Cancer Research. 80:A50-A50
Introduction: The Food and Drug Administration (FDA) expanded access program uses a single-patient use (SPU) mechanism to provide patient access to investigational agents prior to FDA approval and outside clinical trials, in situations where no satis
Autor:
Thomas J. Ryan, Adam Lane, Robin E. Norris, Karen Burns, Laura Agresta, Michael J. Absalon, Christine L Phillips, Erin H. Breese, Benjamin Mizukawa, Robert B. Lorsbach, Maureen M. O'Brien, Lynn Lee, Pankaj B. Desai, John P. Perentesis, H. Leighton Grimes, Alexander A. Vinks, Kana Mizuno
Publikováno v:
Blood. 134:3830-3830
Despite significant advances in AML therapy over the past decades, 30-40% of all young patients with AML will suffer a relapse, after which achieving long-term disease-free survival remains challenging. In pediatric and young adult patients with AML,
Autor:
Joseph G. Pressey, Brian Turpin, Alexandra Plemmons, Hee Kim, Rajaram Nagarajan, Laura Agresta, Joel I. Sorger, Roshni Dasgupta, Sara Szabo
Publikováno v:
Pediatric bloodcancer. 65(6)
Background Desmoid tumors/aggressive fibromatosis (DT/AF) lack a reliably effective medical therapy. Surgical resection may be morbid and does not preclude recurrence. Radiation may carry severe late effects, particularly detrimental in young patient
Autor:
Nancy Ratner, Joseph G. Pressey, Blaise V. Jones, Laura Agresta, Francesco T. Mangano, Sara Szabo, Richard McMasters, Ralph Salloum, Luke Pater, Trent R. Hummel, Christine Fuller
Publikováno v:
Pediatric Blood & Cancer. 66:e27520
Malignant peripheral nerve sheath tumor (MPNST) is a rare soft-tissue sarcoma with an unfavorable prognosis and limited therapeutic options. MPNSTs can be sporadic, but are often associated with neurofibromatosis (NF) 1 and usually arise from preexis